Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma

Oncology

Volumn 72, Issue 1-2, 2007, Pages 69-74

  Rikimaru, Tatsuya ^a   Taketomi, Akinobu ^a   Yamashita, Yo Ichi ^a   Shirabe, Ken ^a   Hamatsu, Takayuki ^a   Shimada, Mitsuo ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cell differentiation; Hepatectomy; Hepatocellular carcinoma; Histone deacetylase 1; Histone deacetylase inhibitor

Indexed keywords

HISTONE DEACETYLASE 1;

AGED; ARTICLE; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; MULTIVARIATE ANALYSIS; PORTAL VEIN; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RISK FACTOR;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 37049001617     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111106     Document Type: Article

References (30)

1. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.
2. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MÁ, Ahn N, Mhof A, Caldas C, Jenuwein T, Esteller M: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
3. Kurdistani SK, Travazoiem S, Grunstein M: Mapping global histone acetylation patterns to gene expression. Cell 2004;117:721-733.
4. Zhang Y, LeRoy G, Seeling HP, Lane WS, Reinberg D: The dermatomyositis specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998;95:279-289.
5. Zhang Y, Ng HH, Bromage EB, Tempst P, Bird A, Reinberg D: Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 1999;13:1924-1935.
6. McKinsey TA, Zhang CL, Lu J, Olson EN: Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 2000;408:106-111.
7. Lu J, McKinsey TA, Zhang CL, Olson EN: Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell 2000;6:233-244.
8. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, Seiser C: Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 1999;19:5504-5511.
9. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528.
10. Marks PA, Jiang X: Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005;4:549-555.
11. Archer SY, Meng S, Shei A, Hodin RA: p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998;95:6791-6796.
12. Sowa Y, Orita T, Hiranabe SM, Mizuno T, Nomura H, Sakai T: Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res 1999;59:4266-4270.
13. Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, Sugimachi K: Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 2003;103:572-576.
14. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-76.
15. Guesdon JL, Ternynck AS: The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 1979;27:1131-1139.
16. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S: A role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007;27:4784-4795. DOI: 10.1128/MCB.00494-07.
17. Whetstine JR, Ceron J, Ladd B, Dufourcq P, Reinke V, Shi Y: Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase. Mol Cell 2005;18:483-490.
18. Huang L: Targeting histone deacetylase for the treatment of cancer and inflammatory diseases. J Cell Physiol 2006;209:611-616.
19. Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM, Bitzer M: Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007;109:2132-2141.
20. Lai JP, Yu C, Moser CD, Aderca I, Han T, Garvey TD, Murphy LM, Garrity-Park MM, Shridhar V, Adjei AA, Roberts LR: SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology 2006;130:2130-2144.
21. Yang WM, Yao YL, Sun JM, Davie JR, Seto E: Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem 1997;272:28001-28007.
22. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH, Kim DY: Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 2004;19:218-224.
23. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92:1300-1304.
24. Bartl S, Taplick J, Lagger G, Khier H, Kuchler K, Seiser C: Identification of mouse histone deacetylase 1 as a growth factor-inducible gene. Mol Cell Biol 1997;17:5033-5043.
25. Schuettengruber B, Simboeck E, Khier H, Seiser C: Autoregulation of mouse histone deacetylase 1 expression. Mol Cell Biol 2003;23:6993-7004.
26. Solari F, Bateman A, Ahringer J: The Caenorhabditis elegans genes egl-27 and egr-1 are similar to MTA1, a member of a chromatin regulatory complex, and are redundantly required for embryonic patterning. Development 1999;126:2483-2494.
27. Toh Y, Pencil SD, Nicolson GL: A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. J Biol Chem 1994;269:22958-22963.
28. Toh Y, Oki E, Oda S, Tokunaga E, Ohno S, Maehara Y, Nicolson GL, Sugimachi K: Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer 1997;74:459-463.
29. Toh Y, Kuwano H, Mori M, Nicolson GL, Sugimachi K: Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br J Cancer 1999;79:1723-1726.
30. Hamatsu T, Rikimaru T, Yamashita Y, Aishima S, Tanaka S, Shirabe K, Shimada M, Toh Y, Sugimachi K: The role of MTA1 gene expression in human hepatocellular carcinoma. Oncol Rep 2003;10:599-604.